1 Markham C. Luke, M.D., Ph.D. Dermatology Clinical Team Leader DDDDP, ODE V, CDER, FDA Combination Topical Products for the Treatment of Acne Vulgaris.

Slides:

Advertisements

Similar presentations

Miles D et al. Proc SABCS 2012;Abstract P

Advertisements

Labeling claims for patient- reported outcomes (A regulatory perspective) FDA/Industry Workshop Washington, DC September 16, 2005 Lisa A. Kammerman, Ph.D.

Results of the Prospective, Randomized, Multicenter FDA Investigational Device Exemption Study of the ProDisc-L Total Disc Replacement Versus Circumferential.

Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.

Interpreting of Patient-Reported Outcomes

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

AGGRENOX TM Advisory Committee Meeting. Manfred Haehl, MD Senior Vice President, Medical & Drug Regulatory Affairs Boehringer Ingelheim Pharmaceuticals,

+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.

Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.

Joint NDAC/PAC meeting October 18, 2007 OTC Cold and Cough Products: Use in Children Advisory Committee Meeting October 18, 2007 Joel Schiffenbauer, MD.

…patient reported outcome (PRO) measure for your clinical study Dr Keith Meadows, DHP Research & Consultancy Ltd.

CR-1 Concluding Remarks and Risk/Benefit Summary Mace L. Rothenberg, MD Professor of Medicine Vanderbilt Ingram Cancer Center.

1 Regulatory Concepts for Dual Indication Combination Products Charu Mullick, M.D. Division of Antiviral Products, CDER U.S. Food and Drug Administration.

Design of Clinical Trials of Antibiotic Therapy for Acute Otitis Media

1 Statistical Perspective Acamprosate Experience Sue-Jane Wang, Ph.D. Statistics Leader Alcoholism Treatment Clinical Trials May 10, 2002 Drug Abuse Advisory.

Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.

Todays Clinical Trials. Tomorrow’s Cures. Robert L. Comis, MD 1 National Coalition for Cancer Research “Cancer 101” Congressional Briefing 09/10/14.

Pulmonary and Allergy Drugs Advisory Committee January 17, 2002 Pulmonary and Allergy Drugs Advisory Committee Meeting Gaithersburg, Maryland January 17,

1 Nonprescription Drugs and Dermatologic and Ophthalmic Drugs Joint Advisory Committee Meeting Over-the-Counter Antifungal Drug Products Treatment of Tinea.

1 Can One Evaluate An Outcomes Claim Based On An Active Controlled Study? Pfizer Response Cardiovascular and Renal Drugs Advisory Committee Rockville,

Clinical Experience With Antibiotic Protocol & RSD N=22 Duration of treatment: 2-4 months Retrospective, open label, clinical trial Responses are based.

1 Statistical Review Dr. Shan Sun-Mitchell. 2 ENT Primary endpoint: Time to treatment failure by day 50 Placebo BDP Patients randomized Number.

Drug - Device Combination Issues : Oncology Perspective Ramzi Dagher, M.D. DODP/CDER/FDA.

March 10th, 2014 Efficacy Endpoints for Anticonvulsant Therapies Interview 1.

DIVISION OF REPRODUCTIVE AND UROLOGIC PRODUCTS Physician Labeling Rule Lisa Soule, M.D.

DHHS / FDA / CDRH 1 FDA Summary CardioSEAL® STARFlex™ Septal Occlusion System with Qwik Load NMT Medical P000049/S3.

Welcome and Introduction Lee S. Simon, MD Division Director Analgesic, Anti-inflammatory and Ophthalmologic Drug Products ODEV/CDER.

Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health (BMG) The use of.

Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.

History of Pediatric Labeling

Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview

Perspectives on Enhancing Consumer Outcomes with Topical Antifungals

Zometa for Patients with Bone Metastases Overview and Review of Study 010 Grant Williams, M.D. Medical Team Leader Division of Oncology Drug Products.

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin plus Cytarabine versus Placebo plus.

Evaluating the Medical Evidence A TOOLKIT FOR THE INTERPRETING THE EFFECTIVENESS OF INTERVENTIONS Niteesh Choudhy, M.D., Ph.D.

1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.

Considerations for Topical Microbicide Phase 3 Trial Designs, an Investigator’s Perspective Andrew Nunn Medical Research Council Clinical Trials Unit London,

General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,

Medical Research and Clinical Trials Rels 300 / Nurs October 2015.

© Guidant 2005 Surrogate Endpoints and Non-randomized Trials Roseann White Humble Biostatistician.

A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.

TAXOL® (paclitaxel) for Adjuvant Treatment of Node Positive Breast Cancer Oncologic Drugs Advisory Committee TAXOL® (paclitaxel) for Adjuvant Treatment.

Conclusions Sidney Cohen, MD Chairman, Department of Medicine Temple University School of Medicine Philadelphia, Pennsylvania Sidney Cohen, MD Chairman,

Acute Bacterial Otitis Media Summary and Charge to the Committee Renata Albrecht, M.D. Division of Special Pathogen and Immunologic Drug Products ODEIV,

Regulatory Considerations for Endpoints Ann T. Farrell, M.D. FDA/CDER/DODP.

Hepatitis C: Perspective on Drug Development Issues Debra Birnkrant, M.D. Director, Division of Antiviral Products FDA Antiviral Drugs Advisory Committee.

Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.

CDER / FDA1 Clinical Study Options for locally acting nasal suspension products Robert J. Meyer, MD Director, Div. Of Pulmonary and Allergy Drug Products.

Zometa for Prostate Cancer Bone Metastases Protocol 039 Amna Ibrahim, M.D. Oncology Drug Products FDA.

Conclusion Senior Vice President Medical & Drug Regulatory Affairs Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, Connecticut Manfred Haehl, MD.

Interface between Cochrane Skin Group reviews and guidelines Annual Cochrane Skin Group Meeting, London, 2016.

1 Clinical Studies Section of Labeling Joseph Porres, M.D., Ph.D. Medical Officer Division of Dermatologic and Dental Drug Products FDA.

Clinical Review Process for New Drug Development and Application

Guidance for review of studies involving HCT/Ps and IND Basics

Patient Focused Drug Development An FDA Perspective

Clinical Research Contribution towards improving Clinical Care

Expedited Drug Approval Programs

Deputy Director, Division of Biostatistics No Conflict of Interest

Bozeman Health Clinical Research

Critical Reading of Clinical Study Results

Improving Acne Outcomes

Coiffier B et al. Proc ASH 2010;Abstract 857.

Suzanne M. Sensabaugh, MS, MBA

A Time for Change for Managing Patients With VTE Who Have Cancer

Issues in TB Drug Development: A Regulatory Perspective

HOPE-3 Trial design: Patients without known cardiovascular disease, and with an intermediate risk of cardiovascular events, were randomized in a 2 x 2.

STOP-CHAGAS Trial design: Asymptomatic patients with serological evidence of T. cruzi were randomized to posaconazole 400 mg BID, benznidazole 200 mg BID,

Introduction to Research Methods in Psychology

Regulatory Perspective of the Use of EHRs in RCTs

Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the Phase 3 VOYAGE 1 and VOYAGE.

Presentation transcript:

1 Markham C. Luke, M.D., Ph.D. Dermatology Clinical Team Leader DDDDP, ODE V, CDER, FDA Combination Topical Products for the Treatment of Acne Vulgaris

2 Fixed-combination Drugs “Two or more drugs may be combined in a single dosage form when each component makes a contribution to the claimed effects and the dosage of each component (amount, frequency, duration) is such that the combination is safe and effective for a significant patient population requiring such concurrent therapy as defined in the labeling for the drug.” - 21 CFR (a)

3 Acne Combination Drugs Combination topical products for the treatment of acne vulgaris require evidence for the contribution of each active component or components that are purported to provide for added efficacy.

4 Fixed-combination Policy Applying the combination drug policy for 2 drugs, component substances A and B having the same endpoint, in a three or four arm clinical trial, success is demonstrated by: (A + B) > A, B > placebo

5 Acne Combination Drugs Currently marketed combination topical drug products for acne have combined a topical antibiotic (erythromycin or clindamycin) [= A] with benzoyl peroxide [= B]. The safety and efficacy of other combinations for the treatment of acne are also being investigated.

6 Acne Combination Drugs Studies to address the combination policy for acne drugs have shown that the most difficult superiority to demonstrate is the contribution of the antibiotic to the efficacy already achievable with benzoyl peroxide alone: (A + B) > B

7 Conclusion Each component of a fixed combination drug for the treatment of acne must demonstrate a contribution to the claimed effects of the drug product. This may be difficult if the contribution of one of the actives (e.g., topical antibiotic) is minimal and hard to discern when combined with another active (e.g., benzoyl peroxide).